– 1. Liu A D, Zhou J, Bi X Y, et al. Aptamer-SH2 superbinder-based targeted therapy for pancreatic ductal adenocarcinoma. Clinical and Translational Medicine. 2021, 11(3): e337
2. Luo P, Yan H, Du J, et al. PLK1 (polo like kinase 1)-dependent autophagy facilitates gefitinib-induced hepatotoxicity by degrading COX6A1 (cytochrome c oxidase subunit 6A1). Autophagy. 2021 Oct;17(10):3221-3237.
3. Liu A D, Zhou J, Bi X Y, et al. Aptamer‐SH2 superbinder‐based targeted therapy for pancreatic ductal adenocarcinoma. Clinical and Translational Medicine. 2021 Mar;11(3):e337. doi: 10.1002/ctm2.337.
4. Li W, Iusuf D, Sparidans R W, et al.Organic anion-transporting polypeptide 2B1 knockout and humanized mice; insights into the handling of bilirubin and drugs.Pharmacological Research.2023: 106724.
5. Pan Q, Xie Y, Zhang Y, et al.EGFR core fucosylation, induced by hepatitis C virus, promotes TRIM40-mediated-RIG-I ubiquitination and suppresses interferon-I antiviral defenses.Nature Communications.2024, 15(1): 652.
6. Liang J, Bi G, Sui Q, et al.Transcription factor ZNF263 enhances EGFR-targeted therapeutic response and reduces residual disease in lung adenocarcinoma.Cell Reports.2024, 43(2).
7. Zhang C, Sun Y X, Yi D C, et al.Neoadjuvant sintilimab plus chemotherapy in EGFR-mutant NSCLC: Phase 2 trial interim results (NEOTIDE/CTONG2104).Cell Reports Medicine.2024
8. Abdelaal N, Ragheb M A, Hassaneen H M, et al.Design, in silico studies and biological evaluation of novel chalcones tethered triazolo [3, 4-a] isoquinoline as EGFR inhibitors targeting resistance in non-small cell lung cancer.Scientific Reports.2024, 14(1): 26647.
